Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GPR3 | P46089 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.37 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | DUSP10 | Q9Y6W6 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30951595 | 1.00 | KDM4E (0.52) | KDM4EGPR3ADORA3TOP2APDPK1 | |
| SCHEMBL16114858 | 0.79 | EGFR (0.37) | KDM4EGPR3ADORA3 | |
| SCHEMBL5741090 | 0.78 | KDM4E (0.52) | KDM4EGPR3ADORA3TOP2APDPK1 | |
| SCHEMBL30549447 | 0.77 | PARP1 (0.42) | KDM4EGPR3PDPK1CYP1A2 | |
| SCHEMBL4900470 | 0.76 | KDM4E (0.47) | KDM4EGPR3PDGFRBPDGFRA | |
| SCHEMBL10667809 | 0.76 | LMNA (0.59) | KDM4ECYP1A2 | |
| SCHEMBL4932780 | 0.75 | LMNA (0.40) | KDM4E | |
| Iodide SCHEMBL10698948 | 0.75 | LMNA (0.58) | KDM4ECYP1A2 | |
| Bromide SCHEMBL10699147 | 0.75 | LMNA (0.58) | KDM4ECYP1A2 | |
| SCHEMBL253096 | 0.73 | GPR3 (0.50) | KDM4EGPR3TOP2APDPK1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250082652-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2025-03-13 | — | — | US | claimed |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | LOMOND THERAPEUTICS, INC. | 2025-01-09 | — | — | US | claimed |
| EP-4460301-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2024-11-13 | — | — | EP | claimed |
| EP-3720493-B1 | COMBINATIONS OF RIPK1- AND IKK-INHIBITORS FOR THE PREVENTION OR TREATMENT OF IMMUNE DISEASES | UNIV KOELN (DE) | 2024-07-24 | — | — | EP | claimed |
| WO-2023131576-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2023-07-13 | — | — | WO | claimed |
| EP-4209213-A1 | SIGNALLING-PATHWAY INHIBITOR COMBINATIONS FOR USE IN THE TREATMENT OF CANCER DISEASES | Universität zu Köln (DE) | 2023-07-12 | — | — | EP | claimed |
| EP-2769980-B1 | PYRAZOLOQUINOLINE DERIVATIVE AS PDE9 INHIBITORS | EISAI R&D MAN CO LTD (JP) | 2016-02-03 | — | — | EP | claimed |
| EP-2769980-A1 | PYRAZOLOQUINOLINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2014-08-27 | — | — | EP | claimed |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-11-07 | — | — | US | claimed |
| US-8563565-B2 | Pyrazoloquinoline derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-10-22 | — | — | US | claimed |
| EP-2178531-A2 | METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS | Yu, Ming (US) | 2010-04-28 | — | — | EP | claimed |
| EP-2038280-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2009-03-25 | — | — | EP | claimed |
| WO-2009006555-A2 | METHODS, COMPOSITION, TARGETS FOR COMBINATIONAL CANCER TREATMENTS | YU, MING (US) | 2009-01-08 | — | — | WO | claimed |
| EP-1888060-A2 | NK-B INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | A. T. Still University of Health Sciences (US) | 2008-02-20 | — | — | EP | claimed |
| WO-2007143523-A2 | FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | WO | claimed |
| US-20060280812-A1 | Compositions and methods for the treatment of muscular dystrophy | A.T. STILL UNIVERSITY OF HEATH SCIENCES | 2006-12-14 | — | — | US | claimed |
| WO-2006127930-A2 | NK-B INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY | A. T. STILL UNIVERSITY OF HEALTH SCIENCES (US) | 2006-11-30 | — | — | WO | claimed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | claimed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | claimed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | KDM4E 4617/4885GPR3 584/4885ADORA3 4/4885 |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | FLT3, PDXK, PHKG1 | KDM4E 2039/4885GPR3 1492/4885ADORA3 3003/4885 |
| US-20130296352-A1 | PYRAZOLOQUINOLINE DERIVATIVES | PDE2A, PDE3A, PDE3B | KDM4E 1309/4885GPR3 270/4885ADORA3 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.